Adam M. Brufsky, MD, PhD | Authors

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

April 18, 2022

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

April 18, 2022

Decision Making in Selecting Treatment in HER2+ BC

May 18, 2021

Experts provide insights on clinical decision-making in the setting of patient with HER2+ breast cancer.

Management Approaches for Patients with HER2+ BC at Risk for Brain Metastases

May 11, 2021

An expert panel of breast oncologists discusses factors they consider when deciding whether to screen a patient with HER2+ breast cancer for brain metastases.

Patient Case: A 37-Year-Old Woman With HER2+/HR- Breast Cancer

May 11, 2021

Adam Brufsky, MD, PhD, presents the case of a 37-year-old woman with HER2+/HR- metastatic breast cancer and polls the audience about screening for brain metastases.

Relapsed/Refractory HER2+ Metastatic Breast Cancer

February 15, 2021

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.

A Closer Look at HER2-Targeted Therapies

October 31, 2018

Dr. Adam Brufsky speaks with Cancer Network about the evolution and future of HER2-targeted therapy.

Bisphosphonates in Breast Cancer: A Triple Winner?

January 15, 2015

We know that bisphosphonates prevent or delay skeletal-related events in breast cancer metastatic to bone, prevent or treat bone loss in patients receiving adjuvant aromatase inhibitor therapy, and decrease bone recurrences and breast cancer–related deaths when used in the adjuvant setting in postmenopausal women with early-stage breast cancer.